Taysha Gene Therapies Basic EPS 2020-2024 | TSHA

Taysha Gene Therapies basic eps from 2020 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
Taysha Gene Therapies Annual Basic EPS
2023 $-0.96
2022 $-3.78
2021 $-4.64
2020 $-3.40
2019 $
Taysha Gene Therapies Quarterly Basic EPS
2024-06-30 $-0.09
2024-03-31 $-0.10
2023-12-31 $0.63
2023-09-30 $-0.93
2023-06-30 $-0.38
2023-03-31 $-0.28
2022-12-31 $-0.96
2022-09-30 $-0.65
2022-06-30 $-0.85
2022-03-31 $-1.32
2021-12-31 $-1.33
2021-09-30 $-1.35
2021-06-30 $-1.09
2021-03-31 $-0.87
2020-12-31 $0.33
2020-09-30 $-1.28
2020-06-30 $-1.95
2020-03-31 $-0.50
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.490B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00